Embedded Files
Even transformative therapies fail if the dosing is wrong.
Innovation is a potent therapy.
innovation is a potent therapy
innovation is a potent therapy
In responding to the Pandemic of Change, it's important to remember that in healthcare, adoption matters as much as innovation.
The therapeutic window of opportunity is wide open—but flooding an organization with change rarely accelerates transformation. More often, it creates resistance and amplifies the most unproductive form of restlessness.
If innovation were a medicine, we'd dose it wisely. Technology may move at digital speed, but people adopt change at human speed.
Digital progress is no longer linear — it’s exponential. And for healthcare, that means change is arriving at a speed many hoped for but few truly expected.
In this dynamic period, healthcare executives must rethink how to lead, adapt, and unlock new value. Healthcare innovators once led from the front—visionaries pushing technology to its limits to improve patient outcomes.
Contrast that with today, where hundreds of millions of people — including clinicians and patients — have embraced user-friendly tools like ChatGPT, creating their own brilliant, unexpected use cases.
As leaders plan their response, it’s critical to remember that even the most transformative therapy can fail if the dosing is wrong. Because in healthcare, sequencing innovation matters as much as the science driving it.
In my Dose Response conversation with Patrick Nowlin — China-based pharma executive turned startup Chief Strategy & Medical Officer, now CEO of Attuned HealthTech — he offered a metaphor every leader should internalize:
“Innovation is like a potent therapy: the dosage, timing, and combination with other ‘agents’ matter… Get it right and you energize a team. Get it wrong and you risk burnout or resistance.”
That’s the tension point of business unusual.
The therapeutic window of opportunity is wide open — but flooding your organization with change won’t accelerate transformation. It will trigger resistance.
Start the continuous innovation infusion
Dose titration matters. So why does it now feel like the moment to initiate a continuous innovation infusion?
Patrick names it clearly:
“Because the science has caught up to the vision… A decade ago, we could imagine the therapies but couldn’t chart a credible path. Today, the path is visible — and that makes conversations more grounded and more urgent.”
That speed of science and digital advancements are why innovation agendas from just a year ago can already feel outdated. Throught this pandemic of change, our sense of what’s possible must be continually reimagined.
But here’s the paradox:
“The limiting factor now isn’t technology; it’s regulation and payer adoption.”
And then Patrick offers a contrarian thought worth sitting with:
“The next big healthcare breakthrough might not be a therapy — it might be a regulatory model that accelerates safe adoption.”
Now that’s interesting.
Patrick goes on to foreshadow two fronts of transformation to watch out for:
1. The therapy side: Griffin Products
AI is accelerating what Patrick calls “Griffin products” — hybrids that combine traits nature never put together, like a lion with eagle wings.
Imagine precision biologics fused with digital diagnostics and paired with novel delivery systems. The result? A broader arsenal of highly targeted tools — and new delivery models to match.
This fusion of modalities has the potential to redefine both what we create — and how we deliver it.
2. The care delivery side: Whole-Person Care
Patrick also sees AI blurring the boundary between clinic and home. Self-management expands. Real-time monitoring becomes ubiquitous. And critically, AI strips away administrative drag so clinicians spend more time with patients, less time at keyboards.
“This isn’t just operational efficiency — it’s a fundamental redefinition of the care experience.”
Marry tech’s agility with healthcare’s rigor
The opportunity ahead is enormous — but to capture this therapeutic window, leaders must learn fast and adapt faster.
Patrick’s advice:
“Healthcare is conservative for good reason — ‘first, do no harm’ matters. We move fast when the platform is burning, like with COVID vaccines. Outside of crisis, adoption can be slow.”
So how do innovators thrive?
“Speak healthcare’s language. Tech proves value through engagement metrics. Healthcare proves value through trials, evidence, outcomes.”
Innovators who frame their impact in clinically familiar terms build trust faster — and trust is the real accelerator.
That’s the win-win: marrying tech’s agility with healthcare’s rigor.
And how can healthcare leaders achieve this balance? Start with empathy.
Patrick challenges a mindset I’ve seen stall too many great ideas:
“Regulators aren’t blocking progress; they’re protecting patients. Payers aren’t stubborn; they’re safeguarding sustainability.”
In other words: develop empathy for all stakeholders — by putting yourself in the seat of regulators, payers, HCPs, and patients.
We’re still in Phase 1 of healthcare's digital dawn. Everyone is learning — regulators, payers, providers, patients, and — yes — healthcare innovators as well.
In this era of connected innovation — the skill of building collaboration across healthcare’s many stakeholders — will be a key competitive advantage.
East meets West: two innovation tempos, one lesson
To close out our conversation, I wanted to explore Patrick’s rare East–West vantage point — and the contrast is instructive.
“China’s innovation culture is velocity-first: ship it at 60%, test, iterate… The West prefers ‘perfect before you launch.’”
The e-prescription story proves the point:
🩸 U.S.: long, deliberate ramp-up over a decade
🩸 China: near-instant uptake
Why? Patrick attributed it to China’s online-first culture, dense delivery infrastructure and regulations enabling virtual clinics.
The global takeaway: Tech alone isn’t enough. Conditions matter, and a one-size-fits-all strategy won’t work. You must calibrate your innovation to each market’s regulatory and health system DNA.
Patrick’s East–West lens shows that the Slipstream exists everywhere — it just looks different depending on where you’re racing.
The Final Dose
In this dynamic period, Patrick’s message to healthcare executives is blunt:
“Leaders can’t lead from the boardroom anymore.”
With the Pandemic of Change redefining opportunities, leaders must get to the front lines, learn from their teams deploying these tools and recognize:
“The danger [of] assuming past experience translates into this new environment. It doesn’t.”
Proximity drives perspective, whether in development of vision, understanding of regulatory and payer stakeholders, or adaptation of innovation agendas to local realities. Success today includes embracing how innovation has shifted from a controlled process to a connected endeavor.
To close out our discussion, I asked Patrick: What should healthcare leaders be asking themselves right now?
He didn’t hesitate:
“Where will exponential change hit my world — and what can I do today to shape it?”
And then:
“The biggest shifts won’t be driven by tech companies alone — they’ll be led by those who understand healthcare’s complexity and can bridge innovation with adoption. The leaders who win will be those who see innovation not as a one-time dose, but as a therapy — carefully managed, adjusted, and scaled over time to deliver sustained impact.”
My takeaways:
🩸 The science has caught up to the vision — now leadership must catch up to the science.
🩸 If innovation were a medicine, we’d dose wisely, build trust, win hearts.
🩸 Innovation without sequencing in a connected system creates resistance, not momentum.
🩸 Empathy isn’t just for patients — it’s essential for regulators, payers, and every stakeholder shaping adoption.
Healthcare leadership today is about building the skillset to deploy innovation, the mindset to rethink what’s possible, the boldset to challenge convention, and the heartset to carry people forward.
Not all at once — but in carefully titrated doses.
>>> Join the Discussion:
🌱 How do you decide the right dose of innovation for your organization?
alex condoleon
alex condoleon
FOUNDER, DOSE OF INNOVATION
Behind Dose of Innovation is Alex Condoleon, a healthcare executive, innovator, and lifelong student of leadership, innovation, and change.
Through articles, frameworks, and Dose Response conversations, Alex explores the ideas, emerging technologies, and transformational shifts reshaping healthcare—translating complex trends into practical insights for leaders navigating an increasingly dynamic world.
His work sits at the intersection of healthcare, technology, leadership, and human behavior, with a particular focus on helping organizations move from possibility to adoption and from innovation to impact.
Because we're still in Phase I.
Page updated
Google Sites
Report abuse